ESTRO shared on X:
“ESTRO26 Young Researcher Award
10-yr RAPCHEM study proves we can safely de-escalate radiotherapy for cT1-2N1 Breast Cancer after chemo.
By tailoring RT to nodal response, patients avoided unnecessary treatment with excellent 10-yr control.”
Other articles about radiotherapy and Breast Cancer on OncoDaily.